Scotiabank Downgrades Syndax Pharmaceuticals to Sector Perform, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst George Farmer has downgraded Syndax Pharmaceuticals (NASDAQ:SNDX) from Sector Outperform to Sector Perform and reduced the price target from $36 to $23.

January 31, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Scotiabank downgraded Syndax Pharmaceuticals from Sector Outperform to Sector Perform and lowered the price target from $36 to $23.
Downgrades by analysts can lead to a negative perception among investors and a potential decrease in stock price. The reduction in price target suggests a lower expected future performance, which may also negatively influence investor sentiment and the stock's short-term price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100